255 related articles for article (PubMed ID: 24890943)
1. MicroRNA expression patterns in adrenocortical carcinoma variants and clinical pathologic correlations.
Duregon E; Rapa I; Votta A; Giorcelli J; Daffara F; Terzolo M; Scagliotti GV; Volante M; Papotti M
Hum Pathol; 2014 Aug; 45(8):1555-62. PubMed ID: 24890943
[TBL] [Abstract][Full Text] [Related]
2. Serum miR-483-5p and miR-195 are predictive of recurrence risk in adrenocortical cancer patients.
Chabre O; Libé R; Assie G; Barreau O; Bertherat J; Bertagna X; Feige JJ; Cherradi N
Endocr Relat Cancer; 2013 Aug; 20(4):579-94. PubMed ID: 23756429
[TBL] [Abstract][Full Text] [Related]
3. The role of microRNA deregulation in the pathogenesis of adrenocortical carcinoma.
Özata DM; Caramuta S; Velázquez-Fernández D; Akçakaya P; Xie H; Höög A; Zedenius J; Bäckdahl M; Larsson C; Lui WO
Endocr Relat Cancer; 2011 Oct; 18(6):643-55. PubMed ID: 21859927
[TBL] [Abstract][Full Text] [Related]
4. Diagnostic and prognostic role of steroidogenic factor 1 in adrenocortical carcinoma: a validation study focusing on clinical and pathologic correlates.
Duregon E; Volante M; Giorcelli J; Terzolo M; Lalli E; Papotti M
Hum Pathol; 2013 May; 44(5):822-8. PubMed ID: 23158211
[TBL] [Abstract][Full Text] [Related]
5. Analysis of circulating extracellular vesicle-associated microRNAs in cortisol-producing adrenocortical tumors.
Perge P; Decmann Á; Pezzani R; Bancos I; Fassina A; Luconi M; Canu L; Tóth M; Boscaro M; Patócs A; Igaz P
Endocrine; 2018 Feb; 59(2):280-287. PubMed ID: 29299796
[TBL] [Abstract][Full Text] [Related]
6. Integrative molecular bioinformatics study of human adrenocortical tumors: microRNA, tissue-specific target prediction, and pathway analysis.
Tömböl Z; Szabó PM; Molnár V; Wiener Z; Tölgyesi G; Horányi J; Riesz P; Reismann P; Patócs A; Likó I; Gaillard RC; Falus A; Rácz K; Igaz P
Endocr Relat Cancer; 2009 Sep; 16(3):895-906. PubMed ID: 19546168
[TBL] [Abstract][Full Text] [Related]
7. High diagnostic and prognostic value of steroidogenic factor-1 expression in adrenal tumors.
Sbiera S; Schmull S; Assie G; Voelker HU; Kraus L; Beyer M; Ragazzon B; Beuschlein F; Willenberg HS; Hahner S; Saeger W; Bertherat J; Allolio B; Fassnacht M
J Clin Endocrinol Metab; 2010 Oct; 95(10):E161-71. PubMed ID: 20660055
[TBL] [Abstract][Full Text] [Related]
8. Adrenocortical carcinoma: review and update.
Erickson LA; Rivera M; Zhang J
Adv Anat Pathol; 2014 May; 21(3):151-9. PubMed ID: 24713984
[TBL] [Abstract][Full Text] [Related]
9. Expression of LIN28 and its regulatory microRNAs in adult adrenocortical cancer.
Faria AM; Sbiera S; Ribeiro TC; Soares IC; Mariani BM; Freire DS; de Sousa GR; Lerario AM; Ronchi CL; Deutschbein T; Wakamatsu A; Alves VA; Zerbini MC; Mendonca BB; Fragoso MC; Latronico AC; Fassnacht M; Almeida MQ
Clin Endocrinol (Oxf); 2015 Apr; 82(4):481-8. PubMed ID: 25200669
[TBL] [Abstract][Full Text] [Related]
10. MiR-142-3p as a potential prognostic biomarker for esophageal squamous cell carcinoma.
Lin RJ; Xiao DW; Liao LD; Chen T; Xie ZF; Huang WZ; Wang WS; Jiang TF; Wu BL; Li EM; Xu LY
J Surg Oncol; 2012 Feb; 105(2):175-82. PubMed ID: 21882196
[TBL] [Abstract][Full Text] [Related]
11. Adrenocortical carcinoma: review of the pathologic features, production of adrenal steroids, and molecular pathogenesis.
Nakamura Y; Yamazaki Y; Felizola SJ; Ise K; Morimoto R; Satoh F; Arai Y; Sasano H
Endocrinol Metab Clin North Am; 2015 Jun; 44(2):399-410. PubMed ID: 26038208
[TBL] [Abstract][Full Text] [Related]
12. Glucose transporter GLUT1 expression is an stage-independent predictor of clinical outcome in adrenocortical carcinoma.
Fenske W; Völker HU; Adam P; Hahner S; Johanssen S; Wortmann S; Schmidt M; Morcos M; Müller-Hermelink HK; Allolio B; Fassnacht M
Endocr Relat Cancer; 2009 Sep; 16(3):919-28. PubMed ID: 19465749
[TBL] [Abstract][Full Text] [Related]
13. MicroRNA Expression Profiling in Adrenal Myelolipoma.
Decmann A; Perge P; Nyíro G; Darvasi O; Likó I; Borka K; Micsik T; Tóth Z; Bancos I; Pezzani R; Iacobone M; Patócs A; Igaz P
J Clin Endocrinol Metab; 2018 Sep; 103(9):3522-3530. PubMed ID: 29982598
[TBL] [Abstract][Full Text] [Related]
14. Clinical and biological significance of miR-378a-3p and miR-378a-5p in colorectal cancer.
Li H; Dai S; Zhen T; Shi H; Zhang F; Yang Y; Kang L; Liang Y; Han A
Eur J Cancer; 2014 Apr; 50(6):1207-21. PubMed ID: 24412052
[TBL] [Abstract][Full Text] [Related]
15. Adrenocortical carcinoma: clinical, morphologic, and molecular characterization.
Stojadinovic A; Ghossein RA; Hoos A; Nissan A; Marshall D; Dudas M; Cordon-Cardo C; Jaques DP; Brennan MF
J Clin Oncol; 2002 Feb; 20(4):941-50. PubMed ID: 11844815
[TBL] [Abstract][Full Text] [Related]
16. Investigation of N-cadherin/β-catenin expression in adrenocortical tumors.
Rubin B; Regazzo D; Redaelli M; Mucignat C; Citton M; Iacobone M; Scaroni C; Betterle C; Mantero F; Fassina A; Pezzani R; Boscaro M
Tumour Biol; 2016 Oct; 37(10):13545-13555. PubMed ID: 27468715
[TBL] [Abstract][Full Text] [Related]
17. Diagnostic and prognostic features in adrenocortical carcinoma: a single institution case series and review of the literature.
Wanis KN; Kanthan R
World J Surg Oncol; 2015 Mar; 13():117. PubMed ID: 25889798
[TBL] [Abstract][Full Text] [Related]
18. Next-generation sequencing reveals microRNA markers of adrenocortical tumors malignancy.
Koperski Ł; Kotlarek M; Świerniak M; Kolanowska M; Kubiak A; Górnicka B; Jażdżewski K; Wójcicka A
Oncotarget; 2017 Jul; 8(30):49191-49200. PubMed ID: 28423361
[TBL] [Abstract][Full Text] [Related]
19. microRNA-431 as a Chemosensitizer and Potentiator of Drug Activity in Adrenocortical Carcinoma.
Kwok GTY; Zhao JT; Glover AR; Gill AJ; Clifton-Bligh R; Robinson BG; Ip JCY; Sidhu SB
Oncologist; 2019 Jun; 24(6):e241-e250. PubMed ID: 30918109
[TBL] [Abstract][Full Text] [Related]
20. Characterization of differential gene expression in adrenocortical tumors harboring beta-catenin (CTNNB1) mutations.
Durand J; Lampron A; Mazzuco TL; Chapman A; Bourdeau I
J Clin Endocrinol Metab; 2011 Jul; 96(7):E1206-11. PubMed ID: 21565795
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]